FDA's Got­tlieb out­lines new goals in bud­get plan, look­ing to spur drug re­views

Scott Got­tlieb

Pres­i­dent Don­ald Trump’s bud­get sought a boost in fund­ing for the FDA and now FDA Com­mis­sion­er Scott Got­tlieb is of­fer­ing his own take on the ini­tia­tives and in­vest­ments the agency plans to pur­sue.

Plans out­lined by Got­tlieb in­clude the cre­ation of two new cen­ters re­lat­ed to drug com­pound­ing and dig­i­tal health.

Pro­mote Do­mes­tic Drug and Bi­o­log­ic Man­u­fac­tur­ing

As phar­ma­ceu­ti­cal and biotech com­pa­nies move to­ward ad­vanced man­u­fac­tur­ing tech­nolo­gies, such as con­tin­u­ous man­u­fac­tur­ing, Got­tlieb said vac­cine sup­plies can be “more eas­i­ly ramped up on short no­tice, and vac­cines them­selves adapt­ed over a short­er time pe­ri­od to ad­dress in­fec­tious dis­eases, such as the flu. The ap­pli­ca­tion of this kind of en­abling tech­nol­o­gy to vac­cine pro­duc­tion has long been a strate­gic pri­or­i­ty for the US.

“By de­vel­op­ing a sci­ence-based frame­work that in­cludes the reg­u­la­to­ry tools and guid­ance for how prod­ucts de­vel­oped in these sys­tems will be eval­u­at­ed, and by fund­ing re­search, de­vel­op­ment and test­ing of the en­abling tech­nolo­gies, the agency can help re­duce the cost and un­cer­tain­ty of adopt­ing these new man­u­fac­tur­ing plat­forms,” he added.

These “small-foot­print, high-tech­nol­o­gy man­u­fac­tur­ing plat­forms” could “re­turn prod­uct man­u­fac­tur­ing to do­mes­tic sites, help­ing to fos­ter job cre­ation,” Got­tlieb said.

Com­pound­ing

FDA is propos­ing to cre­ate, as it did for on­col­o­gy, a “Cen­ter of Ex­cel­lence on Com­pound­ing for Out­sourc­ing Fa­cil­i­ties,” with ex­pand­ed FDA en­gage­ment with out­sourc­ing fa­cil­i­ties and states to help the phar­ma­cy out­sourc­ing in­dus­try grow to meet its in­tend­ed func­tion and ad­here to high­er qual­i­ty stan­dards to pro­tect pa­tient health.

“The Cen­ter of Ex­cel­lence would iden­ti­fy and pro­pose so­lu­tions to mar­ket bar­ri­ers to low­er the cost for phar­ma­cies to be­come out­sourc­ing fa­cil­i­ties. The Cen­ter would pro­vide much-need­ed ed­u­ca­tion and train­ing to im­prove prod­uct qual­i­ty, safe­ty and pur­chas­er con­fi­dence, and help the FDA ad­just its reg­u­la­to­ry over­sight to bet­ter match the scope of pro­duc­tion of an in­di­vid­ual com­pound­ing phar­ma­cy,” Got­tlieb said.

Ad­vance Med­ical De­vice Man­u­fac­tur­ing and Qual­i­ty

FDA is look­ing to es­tab­lish a vol­un­tary pro­gram for de­vice man­u­fac­tur­ers to re­ceive cer­ti­fi­ca­tion for meet­ing ob­jec­tive man­u­fac­tur­ing and prod­uct qual­i­ty cri­te­ria.

“This more mod­ern and nim­ble frame­work would make it more ef­fi­cient for de­vice de­vel­op­ers to in­no­vate man­u­fac­tur­ing process­es in ways that can al­low de­vices to bet­ter meet the needs of pa­tients and the ex­pec­ta­tions of providers – such as through in­tel­li­gent, au­to­mat­ed process­es that mon­i­tor and record man­u­fac­tur­ing qual­i­ty met­rics, in­cor­po­rat­ing fea­tures and tech­no­log­i­cal char­ac­ter­is­tics that can con­tribute to bet­ter op­tions and high­er qual­i­ty that achieves their clin­i­cal pur­pose,” Got­tlieb said.

FDA al­ready is work­ing through the Med­ical De­vice In­no­va­tion Con­sor­tium to de­vel­op the pa­ra­me­ters of the pro­gram.

As part of this ap­proach, the FDA would rec­og­nize third-par­ty cer­ti­fiers and of­fer reg­u­la­to­ry in­cen­tives for those man­u­fac­tur­ers who re­ceive cer­ti­fi­ca­tion demon­strat­ing their qual­i­ty ca­pa­bil­i­ty.

Ad­vance the Use of Re­al-World Ev­i­dence

Got­tlieb said the FDA will ad­vance the use of re­al-world ex­pe­ri­ence “to bet­ter in­form pa­tient care and pro­vide more ef­fi­cient, ro­bust and po­ten­tial­ly low­er-cost ways to de­vel­op clin­i­cal da­ta that can in­form prod­uct re­view and pro­mote in­no­va­tion.”

As part of such ef­forts, he said the FDA will es­tab­lish the abil­i­ty to con­duct near-re­al-time ev­i­dence eval­u­a­tion down to the lev­el of in­di­vid­ual elec­tron­ic health records for at least 10 mil­lion peo­ple in a broad range of US health­care set­tings.

“To­ward these ends, an ex­pand­ed use of nat­ur­al lan­guage pro­cess­ing for the as­sess­ment of in­for­ma­tion sub­mit­ted to the agency would be de­vel­oped in an ef­fort to marked­ly speed recog­ni­tion and re­me­di­a­tion of emerg­ing safe­ty con­cerns,” he added.

Dig­i­tal Health Tech­nol­o­gy

The FDA is work­ing col­lab­o­ra­tive­ly with in­dus­try, pa­tients and providers to es­tab­lish a new par­a­digm for dig­i­tal health tech­nolo­gies un­der which a com­pa­ny could mar­ket low­er-risk prod­ucts with­out FDA pre­mar­ket re­view and mar­ket high­er-risk prod­ucts fol­low­ing a stream­lined FDA pre­mar­ket re­view if the com­pa­ny re­ceives a pri­or third-par­ty cer­ti­fi­ca­tion for en­gag­ing in high-qual­i­ty soft­ware de­sign and test­ing (val­i­da­tion) and on­go­ing main­te­nance.

This reg­u­la­to­ry mod­el would be an ex­pan­sion of the cur­rent pre-cer­ti­fi­ca­tion pi­lot for dig­i­tal health, Got­tlieb said.

In ad­di­tion, the agency aims to cre­ate a “Cen­ter of Ex­cel­lence on Dig­i­tal Health” to es­tab­lish the reg­u­la­to­ry par­a­digm, build new ca­pac­i­ty to eval­u­ate and rec­og­nize third-par­ty cer­ti­fiers, and sup­port a cy­ber­se­cu­ri­ty unit to com­ple­ment the ad­vances in soft­ware-based de­vices.

“To mod­ern­ize and ex­pand its ex­ist­ing ca­pa­bil­i­ties to en­sure the cy­ber­se­cu­ri­ty of med­ical de­vices, the FDA would en­hance its abil­i­ty to co­or­di­nate de­vice-spe­cif­ic re­spons­es to cy­ber­se­cu­ri­ty vul­ner­a­bil­i­ties and in­ci­dents,” he added.

Val­i­dat­ing New Drug De­vel­op­ment

As part of ef­forts to ad­vance the sci­ence of drug de­vel­op­ment, Got­tlieb said the FDA would “build a knowl­edge man­age­ment sys­tem and por­tal to ex­ist­ing and de­vel­op­ing in­for­ma­tion on drug de­vel­op­ment and pre­vi­ous reg­u­la­to­ry de­ci­sions.”

This con­tent man­age­ment plat­form will en­able the FDA to build on evolv­ing in­for­ma­tion and de­ci­sions and iden­ti­fy gaps in reg­u­la­to­ry poli­cies and path­ways en­abling rapid, con­sis­tent re­spons­es to reg­u­la­to­ry ques­tions and pre­vent­ing de­lays in re­sponse to in­no­va­tions in drug de­vel­op­ment.

“As part of this plat­form, the agency al­so would ex­pand its ca­pa­bil­i­ty to quick­ly eval­u­ate new reg­u­la­to­ry ques­tions, us­ing lab­o­ra­to­ry re­search or oth­er ap­pro­pri­ate meth­ods. With the ad­di­tion­al fund­ing, the On­col­o­gy Cen­ter of Ex­cel­lence al­so would stand up a new mod­el for team-based prod­uct re­view that fos­ters col­lab­o­ra­tion across our med­ical prod­uct cen­ters, im­proves re­view ef­fi­cien­cy and ex­pe­dites the de­vel­op­ment of nov­el sci­ence that can im­prove the lives of pa­tients with can­cer,” he said.

Med­ical Prod­ucts Tar­get­ed to Rare Dis­eases

Got­tlieb said the FDA al­so is look­ing to de­vel­op clin­i­cal tri­al net­works to cre­ate an un­der­stand­ing of the nat­ur­al his­to­ry and clin­i­cal out­comes of rare dis­eases.

“The ini­tial fo­cus would be on rare and ul­tra-rare dis­eases, where prod­uct de­vel­op­ment can be chal­leng­ing be­cause of the dif­fi­cul­ty of re­cruit­ing clin­i­cal tri­als,” he said. “FDA has al­ready in­vest­ed, on oc­ca­sion, in the de­vel­op­ment of nat­ur­al his­to­ry mod­els for a small sub­set of rare dis­eases and has ex­per­tise in this area. The FDA would stim­u­late med­ical prod­uct de­vel­op­ment for rare dis­eases by ex­pand­ing and en­hanc­ing the un­der­stand­ing of rare dis­eases and the re­search and drug de­vel­op­ment process­es in this space.”

Mod­ern­ize Gener­ic Drug De­vel­op­ment

On the gener­ic drug front, mean­while, the FDA will cre­ate a new re­view plat­form that would mod­ern­ize gener­ic drug re­view “from a text-based to a da­ta-based as­sess­ment with struc­tured sub­mis­sions and FDA as­sess­ments,” Got­tlieb said.

“This more au­to­mat­ed sys­tem would help to sup­port time­ly de­vel­op­ment and re­view of gener­ic drugs by im­prov­ing clar­i­ty for gener­ic spon­sors, mak­ing ini­tial re­views more ef­fi­cient and de­creas­ing the risk of refuse-to-file let­ters, in­creas­ing the rate of first-cy­cle ap­provals and great­ly in­creas­ing over­all ef­fi­cien­cy.

“This in­vest­ment would al­so sup­port ef­forts to up­date gener­ic drug la­bel­ing, with an ini­tial fo­cus on on­col­o­gy prod­ucts, as part of the agency’s ef­forts to en­sure that pa­tients and their providers have ac­cess to up-to-date in­for­ma­tion to in­form clin­i­cal de­ci­sions,” he added.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

GSK presents case to ex­pand use of its lu­pus drug in pa­tients with kid­ney dis­ease, but the field is evolv­ing. How long will the mo­nop­oly last?

In 2011, GlaxoSmithKline’s Benlysta became the first biologic to win approval for lupus patients. Nine years on, the British drugmaker has unveiled detailed positive results from a study testing the drug in lupus patients with associated kidney disease — a post-marketing requirement from the initial FDA approval.

Lupus is a drug developer’s nightmare. In the last six decades, there has been just one FDA approval (Benlysta), with the field resembling a graveyard in recent years with a string of failures including UCB and Biogen’s late-stage flop, as well as defeats in Xencor and Sanofi’s programs. One of the main reasons the success has eluded researchers is because lupus, akin to cancer, is not just one disease — it really is a disease of many diseases, noted Al Roy, executive director of Lupus Clinical Investigators Network, an initiative of New York-based Lupus Research Alliance that claims it is the world’s leading private funder of lupus research, in an interview.

President Donald Trump (left) and Moncef Slaoui, head of Operation Warp Speed (Alex Brandon, AP Images)

UP­DAT­ED: White House names fi­nal­ists for Op­er­a­tion Warp Speed — with 5 ex­pect­ed names and one no­table omis­sion

A month after word first broke of the Trump Administration’s plan to rapidly accelerate the development and production of a Covid-19 vaccine, the White House has selected the five vaccine candidates they consider most likely to succeed, The New York Times reported.

Most of the names in the plan, known as Operation Warp Speed, will come as little surprise to those who have watched the last four months of vaccine developments: Moderna, which was the first vaccine to reach humans and is now the furthest along of any US effort; J&J, which has not gone into trials but received around $500 million in funding from BARDA earlier this year; the joint AstraZeneca-Oxford venture which was granted $1.2 billion from BARDA two weeks ago; Pfizer, which has been working with the mRNA biotech BioNTech; and Merck, which just entered the race and expects to put their two vaccine candidates into humans later this year.

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.